1. (8-(7-chloro(1,8)naphthyridin-2-yl)-7-oxo-2,5-dithia-8-azabicyclo(4.3.0)non-10-en-9-yl) 4-methylpiperazine-1-carboxylate
2. 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxo-5h-(1,4)dithiino(2,3-c)pyrrol-5-yl-4-methylpiperazine-1-carboxylate
3. Rp 31264
4. Rp-3124
5. Rp-31264
1. Suril
2. 53813-83-5
3. Celexane
4. Rp 31264
5. Rp-31264
6. Lnc9g689vr
7. Celexane; Rp 31264; Suriclone
8. Suriclonum
9. Suriclon
10. Suriclona
11. Suriclon [inn-french]
12. Suriclonum [inn-latin]
13. Suriclona [inn-spanish]
14. Einecs 258-794-1
15. 6-(7-chloro-1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-5h-[1,4]dithiino[2,3-c]pyrrol-5-yl 4-methylpiperazine-1-carboxylate
16. Suriclone [inn:ban]
17. Unii-lnc9g689vr
18. Suriclone [inn]
19. Suriclone [mi]
20. Suriclone [mart.]
21. (r,s)-6-(7-chlor-1,8-naphthyridin-2-yl)-3,5,6,7-tetrahydro-5-oxo-2h-(1,4)dithixino(2,3-c)pyrrol-7-yl-4-methyl-1-piperazinylcarboxylat
22. [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2h-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate
23. Schembl114688
24. Chembl2105561
25. Dtxsid20866362
26. 31264-rp
27. 4-methyl-1-piperazinecarboxylic Acid Ester With (+-)-6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-hydroxy-5h-p-dithiino(2,3-c)pyrrol-5-one
28. Q7646277
29. 1-piperazinecarboxylic Acid, 4-methyl-, 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxo-5h-1,4-dithiino(2,3-c)pyrrol-5-yl Ester
Molecular Weight | 478.0 g/mol |
---|---|
Molecular Formula | C20H20ClN5O3S2 |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 3 |
Exact Mass | 477.0696096 g/mol |
Monoisotopic Mass | 477.0696096 g/mol |
Topological Polar Surface Area | 130 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 763 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
LOOKING FOR A SUPPLIER?